Encorium Group Scores $1.7 million Phase II Contract

Monday, July 16, 2007 07:30 AM

Wayne, Pa.-based CRO Encorium Group has inked a $1.7 million deal to manage a phase II trial in major depressive disorder for an unnamed biotech company based in Japan. Encorium will provide site management and monitoring, data management, biostatistical support and medical writing for the study. Encorium stated it intends to pursue further opportunities in the Japanese market and has made that market one of its key long-term business strategies. Recently, the company signed a $3.8 million contract to conduct phase IIb clinical trials with a new antiviral agent for the treatment of shingles (herpes zoster).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs